Understanding how whole genome duplication affects cancer progression and drug resistance
Causes and Consequences of Whole Genome Duplication in Cancer Progression and Acquired Drug Resistance
This study is looking at how a process called whole genome duplication affects cancer, especially how it can make cancer cells unstable and resistant to treatments, so that patients can better understand why their cancer might change and become harder to treat.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10994646 on NIH RePORTER |
What this research studies
This research investigates the role of whole genome duplication (WGD) in cancer, particularly focusing on how it contributes to chromosomal instability and drug resistance. By utilizing advanced biosensors and imaging techniques, the study aims to observe individual cancer cells over time to understand the mechanisms behind WGD. The researchers are particularly interested in how stress conditions and chemotherapy can trigger WGD, which may lead to worse outcomes in cancers like metastatic Triple Negative Breast Cancer. Patients may gain insights into how their cancer evolves and becomes resistant to treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with metastatic Triple Negative Breast Cancer or other cancers exhibiting drug resistance.
Not a fit: Patients with early-stage cancers or those not experiencing drug resistance may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for treating cancers that exhibit drug resistance due to whole genome duplication.
How similar studies have performed: Previous research has shown that understanding genomic changes in cancer can lead to significant advancements in treatment strategies, suggesting this approach has potential for success.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Regot, Sergi — Johns Hopkins University
- Study coordinator: Regot, Sergi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.